BSE: 532041 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Hindustan Bio Sciences Ltd is a below average quality company.
The key valuation ratios of Hindustan Bio Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Hindustan Bio Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -16.8% | -30.2% | -8.4% | -49% | 2.7% | 2.4% | -23.7% | -16.7% | -1.1% | 1.7% | - |
| Value Creation Index ⓘ | -2.2 | -3.2 | -1.6 | -4.5 | -0.8 | -0.8 | -2.7 | -2.2 | -1.1 | -0.9 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0.8 | 1.3 | 1 | 1 | 3.6 | 1.9 | 1 | 0.4 | 0.9 | 1.1 | 1 |
| Sales YoY Gr. | - | 65.8% | -19.8% | 2% | 245.6% | -45.5% | -46.9% | -58.3% | 114% | 14.1% | - |
| Adj EPS ⓘ | -1.4 | -0.7 | -0.5 | -2.2 | 0.1 | 0.1 | -0.9 | -0.5 | -0 | 0.1 | 0.1 |
| YoY Gr. | - | NA | NA | NA | NA | -27.3% | -1237.5% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 6.7 | 4.7 | 4.2 | 2 | 2.1 | 2.2 | 1.3 | 0.8 | 0.7 | 0.8 | 0.8 |
| Adj Net Profit ⓘ | -1.5 | -0.7 | -0.5 | -2.3 | 0.1 | 0.1 | -0.9 | -0.5 | 0 | 0.1 | 0 |
| Cash Flow from Ops. ⓘ | -0.3 | 0.5 | -0.2 | -0.2 | -1.3 | 0.8 | 0.8 | -0.3 | -0.1 | -1.4 | - |
| Debt/CF from Ops. ⓘ | -3.6 | 2.1 | -8 | -6.9 | -2.6 | 3.2 | 2.5 | -6.3 | -49.3 | -1.8 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 3.7% | -21.7% | 0.6% | 14.1% | ||||
| Adj EPS ⓘ | NA | -11.4% | NA | NA | ||||
| BVPSⓘ | -21.3% | -18.1% | -15% | 6.9% | ||||
| Share Price | 19.3% | 35.8% | 37.3% | 18.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -18.9 | -12.7 | -10.7 | -71.3 | 5.3 | 3.7 | -52.6 | -49.2 | -5.3 | 7.4 | 17.5 |
| Op. Profit Mgn % ⓘ | -184 | -9.8 | -46 | -227.9 | 3.8 | 7 | -90.3 | -116.4 | -3.1 | 6.1 | 15.1 |
| Net Profit Mgn % ⓘ | -190.8 | -58.9 | -48.6 | -220.7 | 3.1 | 4.2 | -90.5 | -119.4 | -4.4 | 5.5 | 12.8 |
| Debt to Equity ⓘ | 0.1 | 0.2 | 0.3 | 0.8 | 1.6 | 1.2 | 1.4 | 2.8 | 3.3 | 3.2 | 2.8 |
| Working Cap Days ⓘ | 3,133 | 1,673 | 2,069 | 1,653 | 459 | 1,001 | 1,543 | 2,688 | 1,219 | 1,134 | 55 |
| Cash Conv. Cycle ⓘ | 383 | 93 | 119 | 99 | 105 | 256 | 132 | 213 | 102 | 140 | 54 |
Return on Equity has increased versus last 3 years average to 17.50%
Sales growth has been subdued in last 3 years 0.64%
Net Profit has been subdued in last 3 years 0.00%
Debt to equity has increased versus last 3 years average to 3.18
Sales growth is not so good in last 4 quarters at -20.46%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.1 | - |
| TTM Sales (₹ Cr.) | 1.1 | - |
| BVPS (₹.) ⓘ | 0.8 | - |
| Reserves (₹ Cr.) ⓘ | -1 | - |
| P/BV ⓘ | 13.18 | - |
| PE ⓘ | 77.60 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 6.86 / 13.47 |
| All Time Low / High (₹) | 0.10 / 106.65 |
| Market Cap (₹ Cr.) | 11 |
| Equity (₹ Cr.) | 2.1 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.76 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 |
| Operating Expenses ⓘ | 2.17 | 1.38 | 1.48 | 3.38 | 3.43 | 1.81 | 1.97 | 0.94 | 0.95 | 0.99 |
| Manufacturing Costs | 0.04 | 0.03 | 0.05 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0 | 0 |
| Material Costs | 1.31 | 0.86 | 0.73 | 0.57 | 2.89 | 1.30 | 0.68 | 0.24 | 0.57 | 0.64 |
| Employee Cost | 0.22 | 0.22 | 0.21 | 0.16 | 0.16 | 0.20 | 0.19 | 0.18 | 0.18 | 0.09 |
| Other Costs ⓘ | 0.60 | 0.28 | 0.49 | 2.61 | 0.35 | 0.29 | 1.09 | 0.51 | 0.20 | 0.26 |
| Operating Profit ⓘ | -1.41 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 |
| Operating Profit Margin (%) | -185.0% | -9.8% | -46.0% | -227.0% | 3.7% | 7.0% | -91.1% | -117.0% | -3.1% | 6.1% |
| Other Income ⓘ | 0 | 0 | 0 | 0.09 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest ⓘ | 0.03 | 0.03 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
| Depreciation ⓘ | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
| Exceptional Items ⓘ | 0 | -1.92 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -1.45 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 |
| Tax ⓘ | 0.01 | 0 | 0 | 0 | 0 | 0.04 | -0.02 | 0 | 0 | 0 |
| Profit After Tax | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 |
| PAT Margin (%) | -192.0% | -165.0% | -48.5% | -220.0% | 3.1% | 4.2% | -91.1% | -120.0% | -4.4% | 5.5% |
| Adjusted EPS (₹) | -1.4 | -2.0 | -0.5 | -2.2 | 0.1 | 0.1 | -0.9 | -0.5 | 0.0 | 0.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 6.91 | 4.82 | 4.33 | 2.05 | 2.16 | 2.24 | 1.30 | 0.79 | 0.75 | 0.80 |
| Share Capital ⓘ | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 |
| Reserves ⓘ | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 |
| Long Term Debt | 0.97 | 0.36 | 0.55 | 0.76 | 2.47 | 1.67 | 0.73 | 1.07 | 1.12 | 2.56 |
| Short Term Debt | 0 | 0.58 | 0.75 | 0.81 | 0.89 | 0.93 | 1.13 | 1.09 | 1.33 | 0 |
| Trade Payables | 0.14 | 0.09 | 0.21 | 0.07 | 0.06 | 0.66 | 0.29 | 0 | 0.06 | 0 |
| Others Liabilities ⓘ | -0.01 | -0.01 | 0 | -0.01 | 0.01 | 0.04 | 0.02 | 0.02 | 0.02 | 0 |
| Total Liabilities ⓘ | 8.01 | 5.84 | 5.84 | 3.68 | 5.60 | 5.55 | 3.48 | 2.97 | 3.28 | 3.37 |
Fixed Assets | ||||||||||
| Gross Block | 0.52 | 0.53 | 0.53 | 0.54 | 0.54 | 0.54 | 0.54 | 0.55 | 0.55 | 0.55 |
| Accumulated Depreciation | 0.45 | 0.46 | 0.47 | 0.48 | 0.48 | 0.49 | 0.50 | 0.51 | 0.51 | 0.52 |
| Net Fixed Assetsⓘ | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 |
| CWIP ⓘ | 1.92 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 0.09 | 0 | 0 | 0.08 | 0.11 | 0.34 | 0 | 0 | 0 | 0 |
| Trade Receivables | 0.32 | 0.47 | 0.47 | 0.32 | 1.67 | 1.36 | 0.62 | 0.14 | 0.45 | 0.44 |
| Cash Equivalents | 0.20 | 0.03 | 0.04 | 0.02 | 0.18 | 0.20 | 0.02 | 0.01 | 0.01 | 0.04 |
| Others Assetsⓘ | 5.40 | 5.27 | 5.27 | 3.21 | 3.57 | 3.60 | 2.80 | 2.79 | 2.79 | 2.86 |
| Total Assets ⓘ | 8.01 | 5.84 | 5.84 | 3.68 | 5.60 | 5.55 | 3.48 | 2.97 | 3.28 | 3.37 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -0.27 | 0.46 | -0.16 | -0.23 | -1.32 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 |
| PBT ⓘ | -1.45 | -0.16 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 |
| Adjustment ⓘ | 0.22 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.01 | 0.01 |
| Changes in Working Capital ⓘ | 0.95 | 0.58 | 0.31 | 2.03 | -1.45 | 0.71 | 1.65 | -0.06 | -0.02 | -1.47 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | -0.02 | 0.02 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0 | 0 |
| Capex | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0 | 0 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 0.30 | -0.63 | 0.18 | 0.21 | 1.50 | -0.81 | -0.93 | 0.34 | 0.05 | 1.43 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0.33 | -0.60 | 0.19 | 0.22 | 1.50 | -0.81 | -0.93 | 0.34 | 0.05 | 1.43 |
| Interest Paid ⓘ | -0.03 | -0.02 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0.03 | -0.17 | 0.01 | -0.02 | 0.17 | 0.01 | -0.18 | -0.01 | 0 | 0.03 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -19.21 | -35.6 | -10.74 | -71.3 | 5.22 | 3.67 | -52.96 | -49.49 | -5.28 | 7.43 |
| ROCE (%) | -16.78 | -30.17 | -8.37 | -49.03 | 2.68 | 2.4 | -23.7 | -16.66 | -1.1 | 1.74 |
| Asset Turnover Ratio | 0.09 | 0.18 | 0.17 | 0.22 | 0.77 | 0.35 | 0.23 | 0.13 | 0.3 | 0.32 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | -12 | 10.25 | N/A | N/A | N/A | -23.5 | Working Capital Days |
| Receivable Days | 378 | 115 | 170 | 139 | 102 | 285 | 350 | 319 | 116 | 155 |
| Inventory Days | 64 | 13 | 0 | 28 | 10 | 43 | 0 | 0 | 0 | 0 |
| Payable Days | 76 | 50 | 76 | 89 | 8 | 102 | 255 | 225 | 21 | 19 |
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.
The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).
Products
The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.
Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.
In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
